S-Biomedic brings novel therapeutic solutions to the skin microbiome.

The skin microbiome - a habitat of billions of beneficial and harmful bacteria - contributes to healthy skin. An imbalance of these bacteria can lead to a variety of skin conditions including acne, eczema, rosacea and ageing.

S-Biomedic uses a targeted modulation-based technology to modify the skin microbiome. This technology can be applied in both the dermatology and cosmetic industries.

We design our products using the latest advances in microbiology and dermatology. Using our technology, beneficial bacteria are selected and combined to generate products that accelerate the rebalancing of a disease microbiome. In this way, we are able to restore a healthy state back to your skin. 

Our first target is acne vulgaris, one of the many skin diseases linked to the distortion of the microbiome.


Veronika OudovaCEO

Veronika is a co-founder and Chief Executive Officer of S-Biomedic. On top of her education in management and entrepreneurship Veronika is inspired by scientific research and its social impact. Veronika has gained multiple years of experience in project and quality management, business development and planning in various industries including both biotech and healthcare.

Bernhard PätzoldCSO

Bernhard completed his PhD in synthetic biology, working together in collaboration with the pharmaceutical industry to engineer bacteria as a living pill. He is a scientific co-founder of S-Biomedic, and is leading the research and product development. His passion is understanding the complex interplay of the bacterial communities that live within and on us. He is fascinated by the untouched potential of active compounds that are naturally produced everyday right on our own skin.

Marc GüellDirector

Marc is a scientific co-founder and non-executive director of S-Biomedic. He is a Wyss Technology Development Fellow at the Wyss Institute under the mentorship of George Church, Harvard Medical School. His research interests are centred on synthetic biology, and biological technology development.


Carlos GallardoDirector

Carlos Gallardo has over 15 years of experience in the pharmaceutical industry regarding licensing, business development and country management. His expertise lies in negotiating strategic company and product acquisitions and investments.

Prof. Dr. Sven Quist

Prof. Dr. Sven Quist investigates the pharmacodynamics of inflammatory medication and drug metabolism, systemic and topical dermatotherapy and magistral formulations. Prof. Quist has experience in leading pharmaceutical studies dealing with different infectious skin diseases. Additionally, he is a qualified pharmacist and a registered medical pharmacist.

Prof. Luis Serrano

Prof. Luis Serrano was previously the head of the Structural & Computational Biology Program at the European Molecular Biology Institute (EMBL) in Heidelberg. Since 2011, he has been the director of the Center for Genomic Regulation (CRG). His group is at the forefront of systems and synthetic biology in Europe. He has authored more than 270 scientific publications and 20 patents.

Prof. Toni Gabaldon

As an ICREA Research Professor Toni Gabaldon focuses on comparative genomics and phylogenomics to study the origin, evolution and function of complex biological systems. He has more than 160 scientific publications in the areas of genomics, microbiology and bioinformatics.

Stacks Image 12859

phone: +49 1573 0066226
mail: contact@sbiomedic.com

Stacks Image 12865

phone: +49 1573 0066226
mail: contact@sbiomedic.com

Clinical Research

Clinical Research


S-Biomedic NV
Represented by managing director Veronika Oudova
Janssen Research Campus

address Turnhoutseweg 30, 2340 Beerse, Belgium
contact phone: +49 15730066226 email: contact@sbiomedic.com
Company and VAT number BE 0668.407.105